Welcome to LookChem.com Sign In|Join Free

CAS

  • or

10429-07-9

Post Buying Request

10429-07-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

10429-07-9 Usage

Description

3β-tosyloxy-5α-androstan-17-one, also known as 3β-(4-methylphenylsulfonyloxy)-5α-androstan-17-one, is a synthetic steroidal compound derived from the modification of the androstane skeleton. It features a tosyloxy group at the 3β position and a 5α-configuration, which contributes to its unique chemical properties and reactivity. 3β-tosyloxy-5α-androstan-17-one serves as a versatile intermediate in the synthesis of various pharmaceutical agents and has potential applications in the development of new therapeutics.

Uses

Used in Pharmaceutical Synthesis:
3β-tosyloxy-5α-androstan-17-one is used as a key intermediate in the synthesis of aminosteroids and rocuronium bromide. It plays a crucial role in the production of these drugs due to its ability to undergo specific chemical reactions that facilitate the formation of the desired pharmaceutical compounds.
Used in the Synthesis of Rocuronium Bromide:
In the field of anesthesiology, 3β-tosyloxy-5α-androstan-17-one is utilized as an intermediate for the synthesis of rocuronium bromide, an amino steroid non-depolarizing neuromuscular blocker. This drug is essential for its muscle relaxant properties during surgical procedures, allowing for better control and safety in various medical interventions.
Used in the Preparation of Antiarrhythmics:
3β-tosyloxy-5α-androstan-17-one also serves as a reagent in the preparation of androstanes, which are compounds with potential antiarrhythmic properties. These androstanes can be further modified and developed into new drugs to treat cardiac arrhythmias, offering a valuable contribution to cardiovascular medicine.

Check Digit Verification of cas no

The CAS Registry Mumber 10429-07-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,0,4,2 and 9 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 10429-07:
(7*1)+(6*0)+(5*4)+(4*2)+(3*9)+(2*0)+(1*7)=69
69 % 10 = 9
So 10429-07-9 is a valid CAS Registry Number.

10429-07-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name 3β-(4-methylphenylsulfonyloxy)-5α-androstan-17-one

1.2 Other means of identification

Product number -
Other names 3β-p-tolylsulphonyloxy-5α-androstan-17-one

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:10429-07-9 SDS

10429-07-9Relevant articles and documents

Conversion of epiandrosterone into 17β-amino-5α-androstane

Merlani,Davitishvili,Nadaraia,Sikharulidze,Papadopulos

, p. 144 - 146 (2004)

A new method for synthesizing 17β-amino-5α-androstane was developed based on tigogenin. The configuration at C-17 was proved by PMR.

METHODS OF ACTIVATING MICROGLIAL CELLS

-

Page/Page column 51; 54-55, (2020/02/23)

The present disclosure provides methods of using compositions that inhibit SH2-containing inositol 5'-phosphatases (SHIPs) for activating microglial cells, as well as methods for using such compositions for treatment or ameliorating of neurodegenerative disorders in a subject.

SHIP INHIBITION TO COMBAT OBESITY

-

Paragraph 00199, (2015/01/16)

The present invention relates to the use of SHIP1 inhibitors and pan-SHIP1/2 inhibitors in various methods, including, without limitation: (i) a method to treat obesity or reduce body fat of an obese subject; (ii) a method to limit bone development in a subject suffering from an osteopetrotic or sclerotic disease; (iii) a method to treat or prevent diabetes; (iv) a method to reduce glucose intolerance or insulin resistance; and (v) a method to lower cholesterol.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 10429-07-9